Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus

Thrombosis Research

Volumn 126, Issue 4, 2010, Pages

  Mortensen, S B ^a   Larsen, S B ^a   Grove, E L ^a   Kristensen, S D ^a   Hvas, A M ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Aspirin; Coronary artery disease; Diabetes mellitus; Platelet aggregation; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; HEMOGLOBIN A1C; THROMBOXANE B2;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

AGED; ASPIRIN; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 77957113521     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.03.013     Document Type: Article

References (47)

1. J.A. Beckman, M.A. Creager, and P. Libby Diabetes and atherosclerosis: epidemiology, pathophysiology, and management JAMA 287 2002 2570 2581
2. T.F. Luscher, M.A. Creager, J.A. Beckman, and F. Cosentino Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II Circulation 108 2003 1655 1661 (Pubitemid 37187795)
3. R. Ajjan, R.F. Storey, and P.J. Grant Aspirin resistance and diabetes mellitus Diabetologia 51 2008 385 390
4. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
5. Standards of medical care in diabetes - 2006 Diabetes Care 29 Suppl 1 2006 S4 42
6. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
7. H. Ogawa, M. Nakayama, T. Morimoto, S. Uemura, M. Kanauchi, and N. Doi Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 300 2008 2134 2141.
8. J. Belch, A. MacCuish, I. Campbell, S. Cobbe, R. Taylor, and R. Prescott The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 337 2008 a1840
9. E.L. Grove, and S.D. Kristensen Update on oral antiplatelet therapy: principles, problems and promises Future Cardiol 5 2009 247 258
10. M. Lordkipanidze, C. Pharand, E. Schampaert, J. Turgeon, D.A. Palisaitis, and J.G. Diodati A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease Eur Heart J 28 2007 1702 1708
11. H.L. Nielsen, S.D. Kristensen, S.S. Thygesen, J. Mortensen, S.B. Pedersen, and E.L. Grove Aspirin response evaluated by the VerifyNow Aspirin System and Light Transmission Aggregometry Thromb Res 123 2008 267 273
12. E.L. Grove, A.M. Hvas, and S.D. Kristensen Aspirin resistance: myth or major problem? Scand J Clin Lab Invest 68 2008 257 259
13. P.A. Gurbel, K.P. Bliden, J. DiChiara, J. Newcomer, W. Weng, and N.K. Neerchal Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study Circulation 115 2007 3156 3164
14. Instructions for use. 18-9-2007. Accumetrics; VerifyNow Aspirin Assay. 14314.F.
15. J.W. Smith, S.R. Steinhubl, A.M. Lincoff, J.C. Coleman, T.T. Lee, and R.S. Hillman Rapid platelet-function assay: an automated and quantitative cartridge-based method Circulation 99 1999 620 625
16. J.L. Coleman, J.C. Wang, and I. Simon Daniel Determination of Individual Response to Aspirin therapy Using the Accumetrics Ultegra RPFA-ASA System Point of care 3 2 2004 77 82
17. D.C. Cardinal, and R.J. Flower The electronic aggregometer: a novel device for assessing platelet behavior in blood J Pharmacol Methods 3 1980 135 158
18. H. Weisser, K. Von Pape, M. Dzijan-Horn, and A. Calatzis Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays: PFA-100 and multiple electrode aggregometry Clin Chem Lab Med 44 2006 A81 A198
19. Human soluble P-Selectin Immunoassay Catalog Number BBE 6 2007 R&D Systems, Inc MN, USA
20. C. Patrono, G. Ciabattoni, E. Pinca, F. Pugliese, G. Castrucci, and S.A. De Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects Thromb Res 17 1980 317 327
21. Thromboxane B2 EIA kit, Catalog No. 519031 2007 Cayman Chemical Company, Ann Arbor MI, USA
22. R: A Language and Environment for Statistical Computing R Foundation for Statistical Computing 2008
23. C. Patrono, and B. Rocca Drug insight: aspirin resistance-fact or fashion? Nat Clin Pract Cardiovasc Med 4 2007 42 50
24. W. Kuliczkowski, A. Witkowski, L. Polonski, C. Watala, K. Filipiak, and A. Budaj Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology Eur Heart J 30 4 2009 426 435
25. P.M. Ridker, J.E. Buring, and N. Rifai Soluble P-selectin and the risk of future cardiovascular events Circulation 103 2001 491 495
26. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, and P. Jimenez-Quevedo Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment Diabetes 54 2005 2430 2435
27. D.J. Angiolillo, E. Bernardo, M. Sabate, P. Jimenez-Quevedo, M.A. Costa, and J. Palazuelos Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease J Am Coll Cardiol 50 2007 1541 1547
28. V. Serebruany, I. Pokov, W. Kuliczkowski, J. Chesebro, and J. Badimon Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease Thromb Haemost 100 2008 76 82
29. G.J. Hankey, and J.W. Eikelboom Aspirin resistance Lancet 367 2006 606 617
30. A.M. Cerbone, N. arone-Palmieri, G. Saldalamacchia, A. Coppola, M.G. Di, and A.A. Rivellese Diabetes, vascular complications and antiplatelet therapy: open problems Acta Diabetol 46 2008 253 261
31. C. Perneby, N.H. Wallen, C. Rooney, D. Fitzgerald, and P. Hjemdahl Dose- and time-dependent antiplatelet effects of aspirin Thromb Haemost 95 2006 652 658
32. J. DiChiara, K.P. Bliden, U.S. Tantry, M.S. Hamed, M.J. Antonino, and T.A. Suarez The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study Diabetes 56 2007 3014 3019
33. J.W. van Werkum, C.A. van der Stelt, T.H. Seesing, C.M. Hackeng, and J.M. ten Berg A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention J Thromb Haemost 4 2006 2516 2518
34. F.M. Pulcinelli, L.M. Biasucci, S. Riondino, S. Giubilato, A. Leo, and R.L. Di COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment Eur Heart J 30 2009 1279 1286
35. E.I. Lev, R.T. Patel, K.J. Maresh, S. Guthikonda, J. Granada, and T. DeLao Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance J Am Coll Cardiol 47 2006 27 33
36. C. Watala, J. Golanski, J. Pluta, M. Boncler, M. Rozalski, and B. Luzak Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control Thromb Res 113 2004 101 113
37. P. Ferroni, S. Basili, A. Falco, and G. Davi Platelet activation in type 2 diabetes mellitus J Thromb Haemost 2 2004 1282 1291
38. C. Watala, M. Boncler, and P. Gresner Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus Suppl Pharmacol Rep 57 2005 42 58
39. A. Iezzi, M.F. Luigia, C. Cuccurullo, C. Corona, C. Patrono, and F. Cuccurullo Abstract 475: Overexpression of Platelet and Monocyte Cyclooxygenase-2 in Coronary Thrombi from Diabetic Patients: A Potential Mechanism of Aspirin Treatment Failure Circulation 2006 114
40. E.L. Grove, A.M. Hvas, and S.D. Kristensen Immature platelets in patients with acute coronary syndromes Thromb Haemost 101 2009 151 156
41. C. Cimminiello Is aspirin effective in diabetic patients? No J Thromb Haemost 3 2005 2615 2616
42. G. Krasopoulos, S.J. Brister, W.S. Beattie, and M.R. Buchanan Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis BMJ 336 2008 195 198
43. J.D. Snoep, M.M. Hovens, J.C. Eikenboom, J.G. van der Bom, and M.V. Huisman Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis Arch Intern Med 167 2007 1593 1599
44. W.H. Chen, X. Cheng, P.Y. Lee, W. Ng, J.Y. Kwok, and H.F. Tse Aspirin resistance and adverse clinical events in patients with coronary artery disease Am J Med 120 2007 631 635
45. P.Y. Lee, W.H. Chen, W. Ng, X. Cheng, J.Y. Kwok, and H.F. Tse Low-dose aspirin increases aspirin resistance in patients with coronary artery disease Am J Med 118 2005 723 727
46. A. Undas, E. Placzkiewicz-Jankowska, L. Zielinski, and W. Tracz Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin J Thromb Haemost 97 2007 1056 1058
47. H.W. Cohen, J.P. Crandall, S.M. Hailpern, and H.H. Billett Aspirin resistance associated with HbA1c and obesity in diabetic patients J Diabetes Complications 22 2008 224 228